One of the possible mechanisms by which SGLT-2 inhibitors reduce the risk of CKD progression and dialysis initiation is related to glycosuria-induced osmotic diuresis and natriuresis, which cause afferent arterial vasoconstriction, leading to a reduction in intraglomerular pressure and glomerular hyperfiltration. Here, SLC5A2 is linked to chronic kidney disease.